In 2025, insurance coverage became increasingly restrictive: The rollbacks were happening everywhere at once: Independence Blue Cross stopped covering GLP-1s for weight loss
The Journal of Clinical Endocrinology & Metabolism , 107(3), 852-860
No Pain, No Gain The main ETFs in the weight-loss drug segment are the Tema Cardiovascular and Metabolic ETF (HRTS), the Roundhill GLP-1 and Weight Loss ETF (OZEM) and Amplify Weight Loss Drug & Treatment ETF (THNR)
If a specific GLP-1 drug, such as Ozempic, is causing intolerable side effects, speak with your healthcare provider about trying another antidiabetic or weight loss medication with the same active ingredient, such as Wegovy (weight loss drug), or another medication from the same class of GLP-1 medications, such as Mounjaro, which may be better tolerated